secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-10-26T23:59:59+00:00
Accession:  0001178913-21-003253
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting
--------------------------------------------------------------------------------

- Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.
- Proposal to approve CEO Dr. Dale Pfost's employment terms passed with 96.3M for, 1.2M against.
- Pfost was engaged as CEO on September 1, 2021.
- Vote satisfied requisite majority under Israeli Companies Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/0001178913-21-003253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer